Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D–dependent mechanism

doi:10.1172/JCI30142

J Clin Invest. 2007 March 1; 117(3): 803–811.

Published online 2007 February 8. doi: 10.1172/JCI30142

PMCID: PMC1784003

Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D–dependent mechanism

Jürgen Schauber,¹ Robert A. Dorschner,¹ Alvin B. Coda,¹ Amanda S. Büchau,¹ Philip T. Liu,² David Kiken,¹ Yolanda R. Helfrich,³ Sewon Kang,³ Hashem Z. Elalieh,⁴ Andreas Steinmeyer,⁵ Ulrich Zügel,⁶ Daniel D. Bikle,⁴ Robert L. Modlin,² and Richard L. Gallo¹

¹Division of Dermatology, University of California, San Diego, and VA San Diego Healthcare System, San Diego, California, USA. ²Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA. ³Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA. ⁴Department of Medicine, Endocrine Unit, Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, California, USA. ⁵Medicinal Chemistry and ⁶Corporate Research Business Area Inflammation, Schering AG, Berlin, Germany.

Address correspondence to: Richard L. Gallo, 3350 La Jolla Village Drive, Mail Code 151, San Diego, California 92161, USA. Phone: (858) 552-8585 ext. 6149; Fax: (858) 552-7436; E-mail: rgallo/at/ucsd.edu.

Received August 22, 2006; Accepted December 12, 2006.

This article has been cited by other articles in PMC.

Abstract

An essential element of the innate immune response to injury is the capacity to recognize microbial invasion and stimulate production of antimicrobial peptides. We investigated how this process is controlled in the epidermis. Keratinocytes surrounding a wound increased expression of the genes coding for the microbial pattern recognition receptors CD14 and TLR2, complementing an increase in cathelicidin antimicrobial peptide expression. These genes were induced by 1,25(OH)₂ vitamin D₃ (1,25D3; its active form), suggesting a role for vitamin D₃ in this process. How 1,25D3 could participate in the injury response was explained by findings that the levels of CYP27B1, which converts 25OH vitamin D₃ (25D3) to active 1,25D3, were increased in wounds and induced in keratinocytes in response to TGF-β₁. Blocking the vitamin D receptor, inhibiting CYP27B1, or limiting 25D3 availability prevented TGF-β₁ from inducing cathelicidin, CD14, or TLR2 in human keratinocytes, while CYP27B1-deficient mice failed to increase CD14 expression following wounding. The functional consequence of these observations was confirmed by demonstrating that 1,25D3 enabled keratinocytes to recognize microbial components through TLR2 and respond by cathelicidin production. Thus, we demonstrate what we believe to be a previously unexpected role for vitamin D₃ in innate immunity, enabling keratinocytes to recognize and respond to microbes and to protect wounds against infection.

Introduction

Innate immunity encompasses all mechanisms that resist infection without the need for prior exposure to the pathogen. The innate immune response is an evolutionarily ancient system that is an important part of mammalian immune defense. In the course of the analysis of this system, several unexpected associations have emerged to explain how factors not previously thought to contribute to the immune response may influence human disease. For example, recent insights into the functions of 1,25(OH)₂ vitamin D₃ (1,25D3) as an immune-modifying agent have illuminated a large body of previously unexplained associations between alterations in vitamin D₃ and infectious disease (1, 2). Elevated 1,25D3 and hypercalcemia have been associated with active pulmonary tuberculosis (3), and lower serum concentrations of the 1,25D3 precursor 25OH vitamin D₃ (25D3) in African Americans correlates with increased susceptibility to infection (4). An explanation for these events has been provided by observations that stimulation of TLR2 increases production of 1,25D3 in monocytes, which in turn leads to an increase in the production of antimicrobial peptides (AMPs) (4). Results of recent studies support a role for vitamin D₃ in the regulation of innate immune functions (5).

Previous findings that 1,25D3 regulates the expression and activation of AMPs in monocytes and keratinocytes in the epidermis (6–8) suggest that in addition to its effects on differentiation and formation of a physical barrier (9, 10), 1,25D3 also provides a stimulus for rapid production of a chemical antimicrobial shield. In particular, 1,25D3 induces the expression of LL-37, a human AMP belonging to the cathelicidin family (11, 12). Cathelicidins are relevant to defense against microbes, as infections develop more easily in mice deficient in the cathelicidin gene (13, 14) and in humans with a deficiency in cathelicidin expression (15). With the observation that cathelicidin is increased with increasing concentrations of 1,25D3 (6–8), the importance of vitamin D₃ to immune defense warrants renewed interest.

Vitamin D₃ is produced from dietary or endogenous precursors under the influence of UVB light (16). Activation of vitamin D₃ to 1,25D3 requires 2 major hydroxylation steps, the first by 25-hydroxylase (CYP27A1) and the second by 1α-hydroxylase (CYP27B1), enzymes located mainly in the human liver and kidney, respectively. However, some 1,25D3-targeted organs such as the epidermis also posses the enzymes to produce 1,25D3 (17). Upon binding to the vitamin D receptor (VDR), 1,25D3 activates target genes through vitamin D–responsive elements (VDREs) in the gene promoter (16). Simultaneously, 1,25D3 induces the vitamin D₃ catabolic enzyme 24-hydroxylase (CYP24A1), thereby initializing its own degradation. Control of 1,25D3-producing and -catabolizing enzymes therefore determines the level of bioactive hormone.

Control of cathelicidin expression follows a pattern consistent with expectations for a gene required for innate immune response, but these events are not known to involve alterations in 1,25D3 levels. Levels of cathelicidin, and several other AMPs, greatly increase after wounding or infection (18), but most classical signaling molecules active in the wound repair response — or microbial ligands that trigger pattern recognition events — have little or no effect on cathelicidin expression (11). Based on observations that cathelicidin is induced by 1,25D3 in vitro (6), we hypothesized that vitamin D₃ signaling may be activated during skin injury. In this study, we investigated the expression of genes influenced by 1,25D3 and attempted to understand this in the setting of wound repair. We show for the first time to our knowledge that injury resulted in enhanced vitamin D₃ metabolism and the subsequent induction of 1,25D3-regulated genes, which led to enhanced expression of essential elements of innate immunity. Our data support what we believe to be a previously unknown role for vitamin D₃ in wound repair and provide insight into factors important to the control of the innate immune response in the skin.

Results

Injury triggers a local increase in 1,25D3 signaling in skin.

The function of elements of cutaneous innate immunity, such as the expression of TLRs and the production of AMPs, is essential for control of infection (13, 19). The expression of AMPs such as the cathelicidin gene CAMP (and the peptide LL-37, which it encodes) increases dramatically in epithelia after injury or infection (18, 20). Recently, production of LL-37 was also shown to be induced by 1,25D3 (6–8) but not by several cytokines, growth factors, or other factors present in wounds (11). The findings that 1,25D3 stimulates cathelicidin expression and that cathelicidin increases following injury (18) prompted us to investigate whether the expression of other elements of innate immunity or 1,25D3-regulated genes are induced after wounding. RNA extracted from skin wound biopsies obtained after sterile full-thickness incision showed the expected increase in cathelicidin expression (Figure (Figure1A).1A). Coincident with this increase in cathelicidin, mRNA for the TLR cofactor CD14 and the 1,25D3 catabolic enzyme CYP24A1 were also induced (Figure (Figure1,1, B and C). Both of these genes were previously shown to be inducible by 1,25D3 (4, 21, 22), but not known to change during the response to injury. This increase in mRNA was accompanied by an increase in CD14 protein expression in keratinocytes at the wound edge and in cells infiltrating the wound (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI30142DS1). In addition, the expression of TLR2, not previously known to be influenced by 1,25D3, also increased as measured by transcript and protein abundance in keratinocytes (Figure (Figure1,1, D and E). The expression of TLR1, TLR4, and TLR6 was not changed.

Figure 1

Injury triggers increased TLR2, CD14, and CYP24A1 in skin.

1,25D3 induces an increase in the expression of TLR2 and CD14.

The finding that multiple, diverse genes under the control of 1,25D3 are increased after injury suggested that the abundance or bioavailability of 1,25D3 may increase in the wound and that these responses may be a previously unrecognized part of the human injury response. We also hypothesized that TLR2 expression is controlled by 1,25D3. To test this, the response of cultured human keratinocytes to 1,25D3 was studied. Similar to the response seen in vivo following injury, levels of CD14 and TLR2 mRNA and protein increased in cultured keratinocytes in response to 1,25D3 (Figure (Figure2,2, A and B). Expression of other TLRs and the TLR coreceptor CD36 remained unchanged. TLR2 and CD14 transcript abundance was also induced by 1,25D3 in keratinocytes differentiated in epidermal constructs (Figure (Figure2C).2C). Patients’ skin treated with topical 1,25D3 also showed increased protein expression of TLR2 (Figure (Figure2D)2D) and cathelicidin (Supplemental Figure 2). This increase in TLR2 seen in patients following a single application of 1,25D3 was not associated with clinical or histological evidence of inflammation. Therefore, these observations show that 1,25D3 induces TLR2 in keratinocytes in vitro and in vivo and that the same set of recognition and response elements of innate immunity are induced both by 1,25D3 and by injury.

Figure 2

The effect of 1,25D3 on the expression of TLRs in cultured keratinocytes.

CYP27B1 is induced by injury and by soluble factors found in wounds.

The finding that genes expressed in injury were the same as those induced by 1,25D3 suggested that a mechanism exists in wounds that leads to an increase in available 1,25D3. To test this hypothesis, we next examined whether wounding, or soluble factors present in the wound, influence CYP27B1, the enzyme responsible for converting inactive 25D3 to active 1,25D3. The expression of this important enzyme following skin injury was to our knowledge previously unknown, but prior observations supported this hypothesis: in skin, the majority of vitamin D₃ is stored in an inactive proform, 7-dehydrocholesterol (23), and some inflammatory mediators such as TNF-α and IFN-γ influence 1,25D3 metabolism in monocytes and macrophages (24–26) as well as in nondifferentiated keratinocytes (27, 28).

In human skin, CYP27B1 expression increased after wounding (Figure (Figure3A).3A). Cultured keratinocytes exposed to TGF-β₁ also showed an increase in CYP27B1 expression, while TNF-α had no effect (Figure (Figure3B).3B). Also, similar to observations made in monocytes (4), CYP27B1 expression in keratinocytes could be induced by activation of TLR2 (Figure (Figure3C).3C). These data demonstrated that injury leads to an increase in the expression of an enzyme capable of inducing a local increase in 1,25D3. This induction may occur secondary to the activity of factors present in the wound, such as IFN-γ or TGF-β₁, or by microbial stimulation of TLR2.

Figure 3

CYP27B1 is increased in response to injury, TGF-β₁, or activation of TLR2.

TGF-β₁ induces cathelicidin, CD14, and TLR2 by CYP27B1-dependent activation of 1,25D3.

To directly test whether the stimulation of CYP27B1 is responsible for the induction of the innate immune molecules we observed in wounds, keratinocytes were next exposed to TGF-β₁ in the presence of 25D3. Prior studies with TGF-β₁, as well as several other molecules associated with wound repair, failed to show that these factors can regulate cathelicidin expression (11). However, we hypothesized that by including 25D3 in culture at a concentration similar to that found in normal skin, TGF-β₁–mediated induction of CYP27B1 could then lead to generation of 1,25D3 and the subsequent induction of cathelicidin, CD14, and TLR2. Neither 25D3 nor TGF-β₁ alone affected expression; however, their simultaneous addition induced cathelicidin, CD14, and TLR2 (Figure (Figure4).4). Specific inhibition of CYP27B1 by itraconazole, or addition of the VDR antagonist ZK159222, blocked this effect (Figure (Figure4).4). These data therefore show that the action of TGF-β₁ and 25D3 was due to the enzymatic generation of 1,25D3.

Figure 4

TGF-β₁ leads to an increase of 1,25D3-responsive genes in wounds by activation of CYP27B1.

Induction of vitamin D₃–regulated immune function in skin wounds is mediated by CYP27B1 activation in vivo.

To further investigate the significance of increased CYP27B1 activation in skin injury, wounds from mice lacking the CYP27B1 enzyme were evaluated for induction of an innate immune response. CD14 is regulated by 1,25D3 (29), and in mouse wounds, CD14 was induced in wild-type animals but not in those lacking CYP27B1 (Figure (Figure5A).5A). In contrast, murine Camp, which is not regulated by 1,25D3 (7), was increased in wounds in both wild-type and CYB27B1-deficient animals (Figure (Figure5B).5B). These data underscore the importance of CYP27B1-activated 1,25D3 production to induce a vitamin D₃–triggered immune response in skin injury.

Figure 5

Activation of CYP27B1 is responsible for increased vitamin D₃ signaling in wounds.

1,25D3 enhances TLR2/6 function by keratinocytes.

In order to explore the functional significance of TLR2 and CD14 induction by increased 1,25D3, keratinocytes were exposed to several TLR ligands, and the antimicrobial response was measured by evaluating the expression of cathelicidin. In contrast to cells grown under basal conditions, keratinocytes pretreated with low doses of 1,25D3 (0.1 nM for 24 hours) responded to Malp-2 but not to other TLR agonists such as LPS, CpG, 19-kDa lipopeptide, and flagellin (Figure (Figure6A).6A). In addition to Malp-2, other ligands of the TLR2/6 heterodimer such as the fungal cell wall component zymosan and the synthetic lipoprotein FSL-1 were also capable of inducing cathelicidin after keratinocytes were activated by 1,25D3 (100 nM; Figure Figure6B).6B). At low concentrations of 1,25D3 (0.1 nM), the significance of the enhanced responsiveness became even more apparent, as evidenced by a dose-dependent increase of cathelicidin expression of up to 60-fold greater than that seen in cells without 1,25D3 (Figure (Figure6C). 6C).

Figure 6

TLR2 function in keratinocytes is increased by 1,25D3.

In order to examine whether this increased responsiveness to TLR2/6 ligands reflects a direct action of 1,25D3 on TLR2 function or an indirect effect related to the changes in keratinocyte differentiation induced by 1,25D3, keratinocytes were studied following differentiation induced by stratification at the air-liquid interface or by increasing the concentration of extracellular calcium. Cultured keratinocyte monolayers incubated with high calcium concentrations (1.7 mM) as an alternative signal to induce terminal differentiation did not respond to TLR2/6 activation by Malp-2 (Figure (Figure6C).6C). This treatment effectively stimulated differentiation, as seen by increased expression of involucrin and altered cell morphology (data not shown). Similarly, differentiated keratinocytes in epidermal constructs did not respond to Malp-2 in the absence of 1,25D3 but did after its addition (Figure (Figure6D).6D). The response to Malp-2 was caused by TLR2, as a neutralizing antibody against TLR2 blocked the 1,25D3-dependent response to both Malp-2 and FSL-1 (Figure (Figure6E).6E). Also, in support of a direct effect of 1,25D3 on TLR2 function were observations of the transcriptional response of the human cathelicidin gene promoter to Malp-2. Keratinocytes were transfected with CAMP promoter constructs, including one with a site-directed disruption of the CAMP VDRE. In the presence of 1,25D3, promoter activity was responsive to Malp-2 only in constructs that included the VDRE (Figure (Figure7A).7A). Also, inhibition of the VDR with ZK159222 inhibited the capacity of Malp-2 to stimulate an increase in cathelicidin mRNA (Figure (Figure7B).7B). Thus, 1,25D3 both induces cathelicidin by itself and enables TLR2 to further increase expression of this AMP.

Figure 7

TLR2 activation signals cathelicidin induction through the vitamin D₃ pathway.

Discussion

Wounding creates a breach in the otherwise intact physical and chemical cutaneous barrier against the outer environment. Shortly after a wound is created, epithelial cells become activated, produce multiple factors to protect against microbial invasion, and trigger recruitment of leukocytes to further defend the wound. These epithelially derived molecules include AMPs, enzymes, cytokines, and growth factors that initiate a complex and incompletely understood process of repair. Only after several hours to days do keratinocytes from the edge of the wound begin to migrate and reepithelialize the injury, reestablishing an effective physical barrier. Prior to final formation of this barrier, it is essential for the unique wound micromilieu to protect the host from infection. Cathelicidin AMPs have been shown to be essential to this process (18), but to our knowledge the elements responsible for control of expression during injury were not previously known.

Recently, 1,25D3 was found to induce human CAMP expression in keratinocytes in vitro and in vivo (6–8), and an observed increase in cathelicidin expression after UVB irradiation was proposed to be caused by an increase in 1,25D3 (30). These observations led us to examine whether the regulation of vitamin D₃ is involved in the wound repair response. We found multiple genes under the influence of vitamin D₃, and TLR2, which to our knowledge was not previously known to be inducible by 1,25D3, was induced in skin after injury. Our results suggest that soluble factors in the wound such as TGF-β₁ stimulate keratinocytes to increase the metabolic conversion of 25D3 to 1,25D3, thus driving the expression and function of human cathelicidin and a TLR2 complex. The increase in TLR2 enabled cells to respond to microbial stimulation and further enhance the AMP response if necessary, while also amplifying the generation of active vitamin D₃. This elegant system of control of innate immunity by vitamin D₃was to our knowledge previously unknown and adds a new element to the understanding of innate immune defense during wound repair.

Keratinocytes possess the complete enzymatic machinery to produce active 1,25D3 from stored inactive proforms (31). The final step of endogenous activation of vitamin D₃ is hydroxylation of 25D3 by CYP27B1. Cytokines such as IFN-γ and TNF-α were found over a decade ago to induce 1,25D3 production in nondifferentiated keratinocytes (27, 28), but the relevance of this was unclear. Our results suggest that the induction of TLR2, CD14, and cathelicidin is a direct consequence of increased vitamin D₃ metabolism. Furthermore, TGF-β₁ was found to increase CYP27B1 and subsequently induce local 1,25D3. Lacking 25D3 as a precursor substrate, inhibiting CYP27B1 enzymatic activity, and blocking the VDR all inhibited the capacity of TGF-β₁ to act in vitro. In vivo, mice lacking the CYP27B1 enzyme failed to respond to skin injury with an increase in 1,25D3-regulated CD14. Further investigations to confirm in vivo that inhibition of CYP27B1 also blocks the AMP response would be helpful, but are hindered by the lack of a VDRE in murine Camp (7). This distinct difference between humans and mice remains to be explained, but may reflect an evolutionary adaptation to the nocturnal nature of mice compared with humans. However, data derived from the results of topical administration of excess 1,25D3 to human volunteers did confirm that 1,25D3 can act in vivo to induce both TLR2 and cathelicidin (Figure (Figure2D). 2D).

Our findings also show that activation of CYP27B1, and subsequent generation of 1,25D3, enables keratinocytes to respond to microbial components such as Malp-2 or zymosan. These observations complement, but are distinct from, recent work in monocytes showing that activation of TLR2 leads to an increase in 1,25D3 (4). One sees that an amplification loop is possible in skin that is not apparent in monocytes (Figure (Figure8).8). 1,25D3 leads to increased TLR2 in keratinocytes, and increased signaling by TLR2 leads to elevated 1,25D3. This does not appear to occur in monocytes and keratinocytes are specific to each cell type. In the epidermis, factors involved in the wound repair process such as TGF-β₁ trigger 1,25D3-dependent immune responses in keratinocytes. In monocytes, TLR2/1 activation increases 1,25D3-dependent antimicrobial activity (4), but vitamin D₃ inhibits TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns (32). Thus, distinct effects on innate immune recognition and response are operative during infection of skin or when microbes come in contact with monocytes.

Figure 8

Schematic model for 1,25D3-regulated innate immune functions in keratinocytes and monocytes.

Future studies of TLR and AMP expression in keratinocytes must include constitutively present elements of the epidermal micromilieu such as precursor forms of vitamin D₃ not typically present in keratinocyte culture systems. Without inclusion of 25D3, the function of CYP27B1 to generate 1,25D3 would not have been detected, and the capacity of TGF-β₁ or TLR2 to influence cathelicidin expression would have been overlooked.

Our results show for the first time to our knowledge that vitamin D₃ signaling is important to microbial recognition and the antimicrobial response during injury. Activated vitamin D₃ generated in the healing process initiates an antimicrobial response and increased sensitivity to microbial challenge. The recognition receptors TLR2 and CD14, which are induced by 1,25D3 are important for defense against a wide range of flora relevant to wound infections because they recognize elements of both Gram-negative and Gram-positive infections such as peptidoglycan and lipoteichoic acid (19), and heterodimers of TLR2 with TLR1 and TLR6 detect triacetylated and diacetylated lipopeptides, respectively (33, 34). In addition, TLR2/6 recognizes fungal wall and mycoplasma components. This is consistent with clinical observations that a large proportion of acute wounds show fungal colonization, yet do not show overt signs of fungal infection (35), and that cathelicidin is fungicidal (36). It will be important to investigate whether disturbed vitamin D₃ metabolism following injury contributes to abnormal wound repair or infection, or whether other disorders characterized by altered innate immune responses may benefit from modification of vitamin D₃ metabolism in skin.

Methods

Patients and treatments.

In order to study human skin wounds, 5-mm full-thickness wounds were induced in volunteers (n = 5) under aseptic conditions with local anesthesia as described previously (18). At 24 hours after incision, 4-mm punch biopsies were taken from the site of injury and immediately fixed in formalin for immunostaining or frozen in liquid N₂ for subsequent RNA isolation. Intact skin from healthy volunteers served as a control (n = 4). In order to examine the effects of topical 1,25D3, healthy skin of volunteers (n = 7) was treated once topically with 1,25D3 (1.0 mM) and left under occlusion for 4 days. Vehicle-treated contralateral skin served as a control. After treatment, skin biopsies were obtained from both sites, fixed in 10% formalin, and embedded in paraffin for immunostaining. All treatments and sample acquisitions, including skin biopsies, were approved by the committees on investigations involving human subjects of the University of California, San Diego, and the University of Michigan. For all procedures, informed consent was obtained.

Animal studies.

Skin wounds were collected from CYP27B1-deficient mice (37) or their wild-type littermates (n = 5 per group) 24 hours after induction of a 5-mm full-thickness wound under aseptic conditions. Noninjured skin from the same animal served as control. Skin samples were immediately frozen for subsequent RNA isolation. All protocols used in the studies were approved by the committees on investigations involving animal subjects at the Veterans Affairs Medical Center, San Francisco, and the University of California, San Diego.

Cell culture and stimuli.

Human keratinocytes were grown in serum-free EpiLife cell culture media (Cascade Biologics) containing 0.06 mM Ca²⁺ and 1× EpiLife Defined Growth Supplement (EDGS) at 37°C under standard tissue culture conditions. Stock cultures were maintained for up to 5 passages in this media with the addition of 50 U/ml penicillin and 50 μg/ml streptomycin. HaCaT keratinocytes were cultured in DMEM (Sigma-Aldrich) with 10% FCS. Cells at 50%–70% confluence were stimulated in fresh medium after preincubation with 1,25D3 (0.1–100 nM for 4–24 hours; Sigma-Aldrich). Alternatively, normal human epidermal keratinocytes were stimulated in the presence of 1,25D3 (0.1–100 nM). Stimuli included TLR2/6 ligands Malp-2 (0.001–0.5 μg/ml; Alexis Biochemicals), FSL-1 (Pam2Cys-GDPKHPKSF, 1–2 μg/ml; Invivogen), and zymosan (50 μg/ml; Invivogen) as well as flagellin (50 ng/ml; Alexis Biochemicals), LPS (1 μg/ml; Sigma-Aldrich), lipoteichoic acid (10 μg/ml; Sigma-Aldrich), 19-kDa lipopeptide (10 μg/ml, a kind gift from S. Krutzik, UCLA, Los Angeles, California, USA), CpG DNA (10 μg/ml; Sigma-Aldrich), Ca²⁺ (1.7 mM), LPS (1 μg/ml; Sigma-Aldrich), TNF-α (20 ng/ml; Chemicon International), and TGF-β₁ (0.1–1 ng/ml; R&D Systems). A TLR2-blocking antibody (clone TL2.1, 5 μg/ml; eBioscience) was used in order to investigate the role of TLR2 signaling. Furthermore, keratinocytes were pretreated with 10^–7 M of either the VDR antagonist ZK159222 or the CYP inhibitor itraconazole before stimulation with TGF-β₁ in the presence of 25D3 (10 nM; Sigma-Aldrich).

Organotypic culture.

Epidermal human skin-like tissue constructs were obtained from MatTek Corp. and cultured according to manufacturer’s instructions. Skin constructs were cultured in maintenance media (EPI-100-MM; MatTek Corp.) and stimulated with Malp-2 (0.1 μg/ml) for 24 hours in the presence of 1,25D3 (100 nM). Skin constructs were cut after stimulation and transferred to Tri zol (Invitrogen) for RNA extraction or immediately frozen in Tissue-Tek (Sakura) for immunostaining.

Quantitative real-time RT-PCR.

RNA was extracted from cells, epidermal constructs, or tissue using Tri zol, and 1 μg RNA was reverse transcribed using iScript (Bio-Rad). Expression of cathelicidin and GAPDH was analyzed by quantitative real-time RT-PCR (qPCR) as described previously (11). Predeveloped TaqMan assay probes (Applied Biosystems) were used for the analyses of the expression of CYP24A1, CYP27B1, CD14, CD36, TLR1, TLR2, TLR4, TLR6, and murine CD14. All analyses were performed in triplicate from 2–5 independent experiments in an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Fold induction relative to the vehicle treated control in in vitro experiments was calculated using the comparative threshold cycle (Ct) method, where ΔCt is ΔCt_stimulant – ΔCt_vehicle, ΔCt is Ct_gene – Ct_GAPDH, and Ct is the cycle at which an arbitrary detection threshold is crossed. For quantification of transcript abundance in tissue samples, target gene expression was normalized to GAPDH and compared with untreated or noninjured skin.

Promoter analysis and site-directed mutagenesis.

To analyze transcriptional activity, a 1,500-bp fragment of the 5′ untranslated region of CAMP was amplified with primers 5′-CACACAGCTAGCGGAACCCCTGGACAACGG-3′ (pGL3 1,500; sense) and 5′-GAGAGACTCGAGGTCTGCCTCCCTCTAGCC-3′ (pGL3 1,500; antisense) using human genomic DNA as a template. Primers were designed to introduce an NheI restriction site at the 5′ end and an XhoI restriction site at the 3′ end of the amplicon. The amplification product was cloned into the TOPO vector (Invitrogen) and transformed into One Shot TOP10 Electrocomp E. coli cells (Invitrogen). After DNA purification using the Wizard Plus, SV Miniprep purification system (Promega), the construct was digested with NheI and XhoI and then subcloned into the promoterless pGL3-basic firefly luciferase vector (Promega). The functional role of a previously described VDRE (6) for the transcription of CAMP was studied by site-directed mutagenesis of the VDRE. The VDRE at position –619 bp to –633 bp relative to the translation start site was deleted with primers 5′-AACTTCTGCTTCAGTGATTCTCAT-3′ (sense) and 5′-ATGAGAATCACTGAAGCAGAAGTT-3′ (antisense) using a protocol published by Prinzen et al. (38). The resulting plasmid lacking the VDRE binding site cloned in the pGL3-basic vector was termed pGL3 1,500–VDRE. All resulting constructs were confirmed by sequencing. For transfection, HaCaT cells were seeded in 24-well plates (BD Biosciences) and used for transfection at 50%–70% confluence. Cells were transfected with CAMP reporter plasmids and 0.1 ng of an internal control Renilla luciferase expression plasmid (Promega) by using 1.5 μl of transfection reagent Fugene 6 (Roche Diagnostics) according to the manufacturer’s instructions. Cells were stimulated with Malp-2 and 1,25D3 6 hours after transfection and incubated 24 hours before harvesting with 50 μl of passive lysis buffer (Promega). Firefly luciferase activity from the CAMP pGL3 reporter vectors and Renilla luciferase activity were measured by the Dual Luciferase Assay system (Promega) in a luminometer (Optocomp I; MGM Instruments). Promoter activity was reported as the ratio between firefly and Renilla luciferase activities in each sample.

Immunostaining.

After fixation in 2% PFA and subsequent washings in PBS, sections from skin tissue or epidermal constructs were blocked in 3% BSA in PBS for 30 minutes at room temperature and stained with anti-cathelicidin LL-37 primary antibody or preimmune serum as described previously (39). After washings in PBS, slides from epidermal constructs were reprobed with an FITC-labeled goat anti-chicken antibody. Nuclei were detected with DAPI. After subsequent washings with PBS, slides were mounted in ProLong Anti-Fade reagent (Invitrogen) and evaluated with an Olympus BX41 microscope (Olympus). Paraffin-embedded, formalin-fixed tissue sections were rehydrated in a series of toluene, ethanol, and PBS. Endogenous peroxidase activity was quenched by 30 minutes incubation in 0.3% H₂O₂ in water, and sections were microwaved for 4 minutes in antigen retrieval solution (0.01 M citric acid, 0.05 M NaOH, pH 6.0). Sections were blocked with 2% goat serum in PBS, 3% BSA, and then incubated with rabbit anti LL-37 (18) or anti-TLR2 (Abcam) primary antibody in PBS, 0.1% BSA. Sections were washed in PBS and detected with biotinylated secondary antibodies (Vector Laboratories) and diaminobenzidine substrate (Sigma-Aldrich) per the manufacturers’ instructions.

Western blot.

Primary keratinocytes were stimulated with 1,25D₃ (100 nM) or vehicle for 24 hours and subsequently lysed in ice-cold lysis buffer (1% Triton-X in PBS containing proteinase inhibitors). After centrifugation, equal amounts of protein were mixed with loading buffer (0.25 M Tris HCl, 10% SDS, 10% glycerol, and 5% β-mercaptoethanol) and loaded onto a 10% Tris-Tricine gel (ISC Bioexpress). After separation, proteins were blotted onto a PVDF membrane (Millipore) and blocked in 5% milk (Bio-Rad) in TBS containing 0.1% Tween20 for 1 hour at room temperature. After washings in TBS containing 0.1% Tween20, membranes were stained with a rabbit polyclonal anti-CD14 (Abcam) or an anti-TLR2 antibody (eBioscience), washed again in TBS containing 0.1% Tween20, and reprobed with a HRP-coupled goat anti-rabbit antibody (Dako). Stained protein was visualized using the Western Lightning system (PerkinElmer) and quantified using ImageJ version 1.36b software (http://rsb.info.nih.gov/ij/). Blots were reprobed with an anti–α-tubulin antibody (Abcam) to ensure equal protein loading. Analyses from 3 independent experiments were performed.

Statistics.

Differences between groups were compared using 2-tailed Student’s t test or Mann-Whitney test as indicated in the figure legends. A P value less than 0.05 was considered significant.

Supplementary Material

Supplemental data

Click here to view.^{(116K, pdf)}

Acknowledgments

This work was supported by a VA Merit award and NIH grants NIH/NIAID HHSN26620040029C, ADB contract no. N01-AI-40029AI48176, AI052453, and AR45676 to R.L. Gallo, by grant BU 2212/1-1 from the Deutsche Forschungsgemeinschaft to A.S. Büchau, and by grant BMBF-LPD 9901/8-119 from the Deutsche Akademie der Naturforscher Leopoldina to J. Schauber.

Footnotes

Nonstandard abbreviations used: AMP, antimicrobial peptide; Ct, threshold cycle; CYP24A1, 24-hydroxylase; CYP27B1, 1,25D3, 1,25(OH)₂ vitamin D₃; 25D3, 25OH vitamin D₃; 1α-hydroxylase; qPCR, quantitative real-time RT-PCR; VDR, vitamin D receptor; VDRE, vitamin D–responsive element.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 117:803–811 (2007). doi:10.1172/JCI30142

References

1. Roth D.E., et al. Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis. J. Infect. Dis. 2004;190:920–927. [PubMed]

2. Wayse V., Yousafzai A., Mogale K., Filteau S. Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. Eur. J. Clin. Nutr. 2004;58:563–567. [PubMed]

3. Barnes P.F., Modlin R.L., Bikle D.D., Adams J.S. Transpleural gradient of 1,25-dihydroxyvitamin D in tuberculous pleuritis. J. Clin. Invest. 1989;83:1527–1532. [PMC free article] [PubMed]

4. Liu P.T., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–1773. [PubMed]

5. Zasloff M. Fighting infections with vitamin D. Nat. Med. 2006;12:388–390. [PubMed]

6. Wang T.-T., et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 2004;173:2909–2912. [PubMed]

7. Gombart A.F., Borregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. Faseb J. 2005;19:1067–1077. [PubMed]

8. Weber G., et al. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J. Invest. Dermatol. 2005;124:1080–1082. [PubMed]

9. Bikle D.D., Oda Y., Xie Z. Calcium and 1,25(OH)2D: interacting drivers of epidermal differentiation. J. Steroid Biochem. Mol. Biol. 2004;89–90:355–360.

10. Tian X.Q., Chen T.C., Holick M.F. 1,25-dihydroxyvitamin D3: a novel agent for enhancing wound healing. J. Cell. Biochem. 1995;59:53–56. [PubMed]

11. Schauber J., Dorschner R., Yamasaki K., Brouha B., Gallo R. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology. 2006;118:509–519. [PubMed]

12. Zaiou M., Gallo R.L. Cathelicidins, essential gene-encoded mammalian antibiotics. J. Mol. Med. 2002;80:549–561. [PubMed]

13. Nizet V., et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature. 2001;414:454–457. [PubMed]

14. Chromek M., et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 2006;12:636–641. [PubMed]

15. Pütsep K., Carlsson G., Boman H., Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet. 2002;360:1144–1149. [PubMed]

16. Brown A.J., Dusso A., Slatopolsky E. Vitamin D. Am. J. Physiol. 1999;277:F157–F175. [PubMed]

17. Overbergh L., et al. Regulation of 25–hydroxyvitamin d–1alpha–hydroxylase by IFN-gamma in human monocytic THP1 cells. J. Steroid Biochem. Mol. Biol. 2004;89–90:453–455.

18. Dorschner R.A., et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 2001;117:91–97. [PubMed]

19. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801. [PubMed]

20. Braff M.H., Bardan A., Nizet V., Gallo R.L. Cutaneous defense mechanisms by antimicrobial peptides. J. Invest. Dermatol. 2005;125:9–13. [PubMed]

21. Zhang D.E., Hetherington C.J., Gonzalez D.A., Chen H.M., Tenen D.G. Regulation of CD14 expression during monocytic differentiation induced with 1 alpha,25-dihydroxyvitamin D3. J. Immunol. 1994;153:3276–3284. [PubMed]

22. Prosser D.E., Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 2004;29:664–673. [PubMed]

23. Lehmann B., Genehr T., Knuschke P., Pietzsch J., Meurer M. UVB-induced conversion of 7-dehydrocholesterol to 1alpha,25-dihydroxyvitamin D3 in an in vitro human skin equivalent. J. Invest. Dermatol. 2001;117:1179–1185. [PubMed]

24. Koeffler H.P., Reichel H., Bishop J.E., Norman A.W. gamma-Interferon stimulates production of 1,25-dihydroxyvitamin D3 by normal human macrophages. Biochem. Biophys. Res. Commun. 1985;127:596–603. [PubMed]

25. Stoffels K., et al. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J. Bone Miner. Res. 2006;21:37–47. [PubMed]

26. Dusso A.S., et al. gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J. Clin. Endocrinol. Metab. 1997;82:2222–2232. [PubMed]

27. Bikle D.D., Pillai S., Gee E., Hincenbergs M. Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology. 1989;124:655–660. [PubMed]

28. Bikle D.D., Pillai S., Gee E., Hincenbergs M. Tumor necrosis factor-alpha regulation of 1,25-dihydroxyvitamin D production by human keratinocytes. Endocrinology. 1991;129:33–38. [PubMed]

29. Matsuura K., et al. Identification of a tissue-specific regulatory element within the murine CD14 gene. J. Biol. Chem. 1992;267:21787–21794. [PubMed]

30. Mallbris L., Edstrom D.W., Sundblad L., Granath F., Stahle M. UVB upregulates the antimicrobial protein hCAP18 mRNA in human skin. J. Invest. Dermatol. 2005;125:1072–1074. [PubMed]

31. Vantieghem K., Kissmeyer A.M., De Haes P., Bouillon R., Segaert S. UVB-induced production of 1,25-dihydroxyvitamin D3 and vitamin D activity in human keratinocytes pretreated with a sterol Delta7-reductase inhibitor. J. Cell. Biochem. 2006;98:81–92. [PubMed]

32. Sadeghi K., et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 2006;36:361–370. [PubMed]

33. Jiang Z., et al. CD14 is required for MyD88-independent LPS signaling. Nat. Immunol. 2005;6:565–570. [PubMed]

34. Hoebe K., et al. CD36 is a sensor of diacylglycerides. Nature. 2005;433:523–527. [PubMed]

35. Vindenes H., Bjerknes R. Microbial colonization of large wounds. Burns. 1995;21:575–579. [PubMed]

36. Lopez-Garcia B., Lee P.H., Yamasaki K., Gallo R.L. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J. Invest. Dermatol. 2005;125:108–115. [PubMed]

37. Bikle D., et al. Mice lacking 25OHD 1alpha–hydroxylase demonstrate decreased epidermal differentiation and barrier function. J. Steroid Biochem. Mol. Biol. 2004;89–90:347–353.

38. Prinzen C., Muller U., Endres K., Fahrenholz F., Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. Faseb J. 2005;19:1522–1524. [PubMed]

39. Braff M.H., Zaiou M., Fierer J., Nizet V., Gallo R.L. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect. Immun. 2005;73:6771–6781. [PMC free article] [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of
American Society for Clinical Investigation